Recent Quotes View Full List My Watchlist Create Watchlist Indicators DJI Nasdaq Composite SPX Gold Crude Oil EL&P Market Index Markets Stocks ETFs Tools Overview News Currencies International Treasuries Seagen Inc (NQ: SGEN ) N/A UNCHANGED Last Price Updated: 4:00 PM EST, Dec 13, 2023 Add to My Watchlist Quote Overview Detailed Quote Charting Historical Prices News All News News Headlines Press Releases Research Quarterly Reports Insider Filings Other Filings All News about Seagen Inc < Previous 1 2 ... 11 12 13 14 15 16 17 18 Next > Seagen to Present at the Morgan Stanley 19th Annual Global Healthcare Conference September 09, 2021 From Seagen Inc. Via Business Wire Seagen to Highlight Research From 16 Presentations Across Multiple Tumor Types at ESMO 2021 September 08, 2021 From Seagen Inc. Via Business Wire A Look Into Seagen's Price Over Earnings August 24, 2021 In the current market session, Seagen Inc. (NASDAQ:SGEN) is trading at $165.17, after a 0.24% drop. However, over the past month, the stock increased by 14.36%, and... Via Benzinga Week In Review: RemeGen Out-Licenses Rights For HER2 ADC To Seagen In $2.6 Billion Deal August 14, 2021 Yantai's RemeGen out-licensed global rights (ex-Asia) for its novel HER2-targeted ADC to Seagen in a $2.6 billion deal. Seagen, an antibody conjugate company, will pay $200 million upfront and up to... Via Talk Markets Earnings Scheduled For July 29, 2021 July 29, 2021 Companies Reporting Before The Bell • Smith & Nephew (NYSE:SNN) is projected to report earnings for its second quarter. • Cohen & Co (AMEX:COHN) is... Via Benzinga Earnings Scheduled For April 29, 2021 April 29, 2021 Companies Reporting Before The Bell • OSI Systems (NASDAQ:OSIS) is estimated to report quarterly earnings at $1.33 per share on revenue of $290.51 million. •... Via Benzinga Seagen Bets On China's ADC In $2.6B Cancer Deal August 09, 2021 Seagen Inc (NASDAQ: SGEN) and RemeGen Co Ltd have entered into an exclusive worldwide licensing agreement to develop and commercialize disitamab vedotin... Via Benzinga Seagen and RemeGen Announce Exclusive Worldwide License and Co-Development Agreement for Disitamab Vedotin August 09, 2021 From Seagen Inc. Via Business Wire Seattle Genetics (SGEN) Q2 2021 Earnings Call Transcript July 30, 2021 SGEN earnings call for the period ending June 30, 2021. Via The Motley Fool Topics Earnings Exposures Financial Seagen Reports Second Quarter 2021 Financial Results July 29, 2021 From Seagen Inc. Via Business Wire Astellas - Seagen's PADCEV Wins Full FDA Approval And Expanded Label In Tough-To-Treat Urothelial Cancer July 12, 2021 The FDA granted full approval and a label expansion for Seagen Inc (NASDAQ: SGEN) - Astellas Pharma Inc's (OTC: ALPMF) PADCEV to treat... Via Benzinga Exposures Product Safety The Daily Biotech Pulse: Merck's Disappointing Q2, Atreca Falls On Data, FDA Nod For Viatris, Nuvalent, Icosavax IPOs July 29, 2021 Here's a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech Stocks Hitting 52-week Highs July 28) AbbVie Inc. (NYSE: ABBV)... Via Benzinga Exposures Product Safety The Week Ahead In Biotech (July 25-31): Big Pharma Earnings, Iterum FDA Decision, Alzheimer's Conference, IPOs and More July 25, 2021 Biotech stocks rebounded in the week ended July 23, thanks to the broader market strength. The sector also benefitted from the optimism that was set in motion by the solid start... Via Benzinga Exposures Product Safety U.S. FDA Grants Regular Approval and Expands Indication for PADCEV® (enfortumab vedotin-ejfv) for Patients with Locally Advanced or Metastatic Urothelial Cancer July 09, 2021 From Seagen Inc. Via Business Wire Seagen to Host Conference Call and Webcast Discussion of Second Quarter 2021 Financial Results on July 29, 2021 July 08, 2021 From Seagen Inc. Via Business Wire Updated Analysis Show Seagen's Tukysa Extended Median OS to Two Years with Benefits Maintained in Breast Cancer June 03, 2021 Seagen Inc (NASDAQ: SGEN) has announced that improvements in overall survival (OS) and progression-free survival (PFS) were maintained with long-term follow-up... Via Benzinga Seagen Announces Long-Term Results from TUKYSA® (tucatinib) Pivotal Trial in Patients with HER2-Positive Breast Cancer During the Virtual Scientific Program of the 2021 ASCO Annual Meeting June 03, 2021 From Seagen Inc. Via Business Wire Seagen to Present at the Goldman Sachs 42nd Annual Global Healthcare Conference June 02, 2021 From Seagen Inc. Via Business Wire The Week Ahead In Biotech: ASCO Presentations Front And Center, FDA Decisions Due For Scynexis, Liminal And Alkermes May 31, 2021 After having declined through the first half of the week, biotech stocks staged a recovery to close higher in the trading week ended May 28. Broader market sentiment and company-... Via Benzinga Exposures Product Safety Seagen and Astellas Announce Updated Results from Two Trials of PADCEV® (enfortumab vedotin-ejfv) in Patients with Locally Advanced or Metastatic Urothelial Cancer Not Eligible for Cisplatin Chemotherapy May 19, 2021 From Seagen Inc. Via Business Wire Got $5,000? These 3 Growth Stocks Are Trading Near Their 52-Week Lows May 12, 2021 Although they have been struggling recently, these stocks remain attractive buys over the long term. Via The Motley Fool Stocks That Hit 52-Week Lows On Friday April 30, 2021 Friday morning saw 14 companies set new 52-week lows. Points of Interest: Lufax Holding (NYSE:LU) was the largest, in terms of market cap, to set a new 52-week low... Via Benzinga Seattle Genetics (SGEN) Q1 2021 Earnings Call Transcript April 30, 2021 SGEN earnings call for the period ending March 31, 2021. Via The Motley Fool Topics Earnings Exposures Financial Recap: Seagen Q1 Earnings April 29, 2021 Shares of Seagen (NASDAQ:SGEN) decreased in after-market trading after the company reported Q1 results. Quarterly Results Earnings per share were up 31.63% over the past year to... Via Benzinga Seagen Reports First Quarter 2021 Financial Results April 29, 2021 From Seagen Inc. Via Business Wire The Daily Biotech Pulse: Athenex, NeoGenomics And Amryt In M&A Mix, European Nod For Roche's Cancer Immunotherapy, Earnings Deluge Continues May 05, 2021 Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech Stocks Hitting 52-week Highs May 4) AbbVie Inc. (NYSE: ABBV)... Via Benzinga The Daily Biotech Pulse: Clinical Setback For Adverum, Galera Posts Data Readout, Moderna To Invest In Vaccine Manufacturing, Decision Day For Ardelyx April 29, 2021 Here's a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech Stocks Hitting 52-week Highs April 28) Axonics, Inc. (NASDAQ:... Via Benzinga Seagen to Showcase Data from Growing Oncology Portfolio During Virtual Scientific Program of the 2021 ASCO Annual Meeting April 29, 2021 From Seagen Inc. Via Business Wire Seattle Genetics's Earnings Outlook April 28, 2021 Seattle Genetics (NASDAQ:SGEN) announces its next round of earnings this Thursday, April 29. Here is Benzinga's everything-that-matters guide for this Thursday's Q1 earnings... Via Benzinga The Week Ahead In Biotech (April 25-May 1): FDA Decisions For Sol-Gel, Protalix Bio, Ardelyx April 24, 2021 Biopharma stocks came back from the weakness seen in the first two sessions to close the week ended April 23 higher. Johnson & Johnson (NYSE: JNJ) and Roche Holding AG (OTC:... Via Benzinga Exposures Product Safety < Previous 1 2 ... 11 12 13 14 15 16 17 18 Next > Data & News supplied by www.cloudquote.io Stock quotes supplied by Barchart Quotes delayed at least 20 minutes. By accessing this page, you agree to the following Privacy Policy and Terms and Conditions.
